Skin toxicity of BRAF and MEK inhibitors
نویسندگان
چکیده
Inhibitory mutovan?Š BRAF kin??zy dohromady s inhibitory MEK jsou jednou z alternativ modern? syst?Šmov?Š l?ŠÄby metastazuj?c?ho melanomu. a t?Š?ž prok??zaly efekt v adjuvantn?m pod??n?. Tyto l?Šky vykazuj? specifick?Š spektrum ne?ž??douc?ch ??Äink??, p??iÄem?ž ko?žn? toxicita pat??? mezi nejÄastÄ?j??? je pro jednotliv?Š kombinace l?Šk?? vysoce specifick??. P??edkl??dan?? Äl??nek shrnuje typy toxicity inhibitor?? p??ihl?Šdnut?m k etiopatogenetick??m mechanism??m, hodnocen? terapii.
منابع مشابه
Molecular Pathways Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF Tumors
The RAS–RAF–MEK (MAP–ERK kinase)–ERK (extracellular signal–regulated kinase) pathway plays a central role in driving proliferation, survival, and metastasis signals in tumor cells, and the prevalence of oncogenic mutations in RAS and BRAF and upstream nodes makes this pathway the focus of significant oncology drug development efforts. This focus has been justified by the recent success of BRAF ...
متن کاملMolecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF Tumors
The RAS–RAF–MEK (MAP–ERK kinase)–ERK (extracellular signal–regulated kinase) pathway plays a central role in driving proliferation, survival, and metastasis signals in tumor cells, and the prevalence of oncogenic mutations in RAS and BRAF and upstream nodes makes this pathway the focus of significant oncology drug development efforts. This focus has been justified by the recent success of BRAF ...
متن کاملCutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
IMPORTANCE The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor trametinib dimethyl sulfoxide (CombiDT therapy) increase...
متن کاملInhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant melanoma, but their efficacy is limited by both intrinsic and acquired resistances. Activation of the PI3K pathway can mediate resistance to these agents, providing a strong rationale for combination therapy in melanoma. Here, a panel of nine low-passage human metastatic melanoma cell lines with BRAF mutations was test...
متن کاملPotential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. However, as has been observed previously with similarly successful targeted therapies, acquired resistance to these agents is an emerging problem that limits their clinical benefit. Several recent studies from our laboratory and others ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologie
سال: 2021
ISSN: ['1803-5345', '1802-4475']
DOI: https://doi.org/10.36290/xon.2021.033